Efficacy of Subcutaneous Semaglutide Dose Escalation in Reducing Insulin in Patients With Type 2 Diabetes

More on GLP-1 and incretin signalling

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026

• Retatrutide reduces bodyweight in obesity and type 2 diabetes

  Lancet · 4 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026